Novartis v. Lupin: MAYZENT Siponimod Patent Suit Dismissed Without Prejudice
Novartis AG filed suit against generic challenger Lupin Limited in Delaware, asserting two patents covering its siponimod (MAYZENT) multiple sclerosis tablets. After 207 days, Novartis voluntarily dismissed all claims without prejudice under Rule 41(a)(1)(A)(i), leaving both parties to bear their own legal costs.
Novartis drops MAYZENT infringement claims against Lupin before merits ruling
On 9 May 2025, Novartis AG and its pharmaceutical affiliate filed suit against Lupin Limited in the District of Delaware, asserting infringement of US11944602B2 and US8492441B2. Both patents relate to siponimod — marketed as MAYZENT — a selective sphingosine-1-phosphate receptor modulator approved for secondary progressive multiple sclerosis. The accused products encompass Lupin’s proposed generic siponimod fumaric acid tablets at 0.25 mg, 1 mg, and 2 mg base-equivalent doses.
On 2 December 2025, Novartis filed a voluntary notice of dismissal pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i), terminating all claims without prejudice. Because this rule permits unilateral dismissal before the opposing party has served an answer or moved for summary judgment, no court order was required. Each party was directed to bear its own attorneys’ fees and costs, and no merits ruling was issued on either patent.
The 207-day duration and Rule 41(a)(1)(A)(i) mechanism together suggest the dismissal preceded substantive motion practice — consistent with early-stage resolution, potentially reflecting licensing discussions, ANDA amendment, or a commercial arrangement the public record does not disclose. The without-prejudice designation means Novartis retains the right to re-assert both patents against Lupin should circumstances change, an important strategic reserve in the competitive MAYZENT generics landscape.
Filing to Voluntary dismissal in 207 days
207-day litigation window — resolved before substantive motion practice typically concludes
Voluntarily dismissed: what the without-prejudice ruling means for both parties
Rule 41(a)(1)(A)(i) allows unilateral exit before answer
Federal Rule of Civil Procedure 41(a)(1)(A)(i) permits a plaintiff to dismiss an action unilaterally by filing a notice before the defendant serves an answer or a motion for summary judgment. No court approval is needed. This mechanism signals the dismissal occurred very early in proceedings — before Lupin had formally responded on the merits — and carries no judicial finding on validity or infringement.
No merits adjudicationPublic record is silent on whether a settlement was reached
A dismissal without prejudice means Novartis may re-file the same claims in the future; the patents remain fully enforceable and unchallenged. This is distinct from a with-prejudice dismissal, which would bar re-assertion. The public record states only ‘without prejudice’ — it does not confirm or deny whether a licensing agreement, ANDA modification, or commercial arrangement was reached. Practitioners should not assume settlement, nor rule it out.
Patents remain assertableLupin faces unresolved patent risk on MAYZENT generics
Because no invalidity or non-infringement finding was made, Lupin cannot claim a cleared path to market based on this proceeding. Both asserted patents — US11944602B2 and US8492441B2 — remain in force. Lupin may face renewed litigation if it pursues MAYZENT generic launch, and the without-prejudice nature of the dismissal means Novartis preserves full enforcement optionality. Lupin’s ANDA status and any paragraph IV certifications remain relevant monitoring items.
No clearance grantedMAYZENT exclusivity window remains intact for Novartis
Voluntary dismissal without prejudice leaves Novartis’s IP position around siponimod substantively unchanged. The two asserted patents continue to serve as barriers to generic entry. For competing ANDA filers and the broader MS therapeutics market, this outcome signals neither strength nor weakness in the patents’ validity — it simply resets the litigation clock. Market entrants should treat the IP landscape as unresolved and conduct independent FTO analysis before any commercialisation decision.
Generic entry still blocked by IPFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novartis, AG | Company | Pharmaceutical innovator — holder of US11944602B2 and US8492441B2 covering siponimod (MAYZENT)Search in Eureka ↗ |
| Defendant | Lupin Limited | Individual | Indian generic pharmaceutical manufacturer seeking U.S. market entry for siponimod tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Novartis, AGSearch in Eureka ↗ |
| Defendant counsel | Alexandra M. Ewing | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant counsel | Frederick L. Cottrell , III | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant law firm | Richards Layton & Finger PA | Law Firm | Representing Lupin LimitedSearch in Eureka ↗ |
| Presiding judge | Judge John F. Murphy | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice states that Novartis dismissed ‘all claims without prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i),’ with each party bearing its own costs. This phrasing confirms a clean procedural exit with no admission, no invalidity finding, and no infringement determination. The cost-neutrality clause is standard for Rule 41(a)(1) notices and does not signal relative leverage. Both US11944602B2 and US8492441B2 remain unchallenged in this proceeding.
US11944602B2 & US8492441B2 — Siponimod formulations for multiple sclerosis
US11944602B2 is a later-prosecution patent with application number US17/209940, likely representing continuation or formulation-focused claims in the siponimod family. US8492441B2 (application US12/655049) represents an earlier foundational patent covering siponimod compound or composition aspects. Together, the two patents bracket both early compound IP and more recent formulation-specific claims covering MAYZENT tablets at 0.25 mg, 1 mg, and 2 mg base-equivalent doses — the exact strengths targeted in Lupin’s generic application.
Siponimod holds regulatory approval for secondary progressive multiple sclerosis, a commercially significant indication with limited approved oral therapies. Controlling the formulation and compound IP around this molecule gives Novartis layered exclusivity that is difficult for generic challengers to fully design around. The two-patent assertion strategy is consistent with standard Hatch-Waxman practice: overlapping patent families extend effective exclusivity beyond any single patent’s expiry. For the broader S1P modulator class, this case reinforces that even early exits preserve robust patent positions.
Should you run an FTO against US11944602B2 and US8492441B2?
Any pharmaceutical company developing or commercialising oral siponimod formulations — including tablet strengths of 0.25 mg, 1 mg, or 2 mg base-equivalent — should treat both asserted patents as active risks. The without-prejudice dismissal in this case grants no FTO coverage to third parties. Lupin’s situation illustrates that even a voluntarily dismissed suit does not clear the path to market; Novartis retains full re-assertion rights. ANDA filers, 505(b)(2) applicants, and out-licensees in the S1P receptor modulator space should prioritise independent claim mapping against both patents before any IND, NDA, or commercial launch milestone.
PatSnap Eureka’s FTO Search Agent can rapidly map your siponimod formulation against the claim trees of US11944602B2 and US8492441B2, surfacing prior art, claim differentiation opportunities, and prosecution history estoppel relevant to non-infringement arguments. Eureka’s litigation monitoring layer also tracks any new ANDA suits Novartis files in Delaware or other districts, giving your IP and regulatory teams early warning before a 30-month stay is triggered. Run your FTO search directly in Eureka to get a landscape view of the full siponimod patent family.
Run a freedom-to-operate analysis on US11944602B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent infringement cases: S1P modulators and MS therapeutics
Explore comparable Hatch-Waxman and ANDA patent suits in Delaware District Court involving multiple sclerosis therapeutics and small-molecule formulation IP.
What this case signals for the MS therapeutics and ANDA patent landscape
A without-prejudice exit in a pharma ANDA case rarely signals a clean resolution — the underlying IP tension typically persists.
Without-prejudice dismissal preserves Novartis’s full enforcement arsenal
Novartis retains the ability to reassert US11944602B2 and US8492441B2 against Lupin at any time. Generic manufacturers and ANDA holders targeting siponimod should not treat this dismissal as a market clearance event. Independent FTO analysis against both patents remains essential before any commercial launch decision.
Early Rule 41(a)(1)(A)(i) exit suggests pre-answer resolution dynamic
The procedural mechanism used — filing a notice before Lupin answered — is consistent with early-stage negotiation concluding before costly motion practice. Whether that reflects a licensing arrangement, ANDA amendment, or tactical withdrawal is not publicly disclosed. Either way, the litigation timeline suggests minimal discovery cost was incurred by either party.
Novartis v Lupin — key questions answered
Novartis dismissed all claims under Rule 41(a)(1)(A)(i), which permits unilateral dismissal before the defendant serves an answer. A without-prejudice dismissal means Novartis can re-assert US11944602B2 and US8492441B2 against Lupin in future litigation. No merits ruling was issued, and neither patent was found invalid or not infringed.
Novartis asserted two patents: US11944602B2 (application US17/209940) and US8492441B2 (application US12/655049). Both relate to siponimod, the active ingredient in MAYZENT, which is approved for secondary progressive multiple sclerosis. The accused products were Lupin’s proposed siponimod fumaric acid tablets at 0.25 mg, 1 mg, and 2 mg base-equivalent doses.
No. The dismissal was without prejudice and involved no invalidity or non-infringement determination. Both asserted patents remain in force and enforceable. Lupin would still need to address these patents — through litigation, licensing, or ANDA paragraph IV proceedings — before a risk-free commercial launch. Third parties should not treat this dismissal as market clearance.
The case lasted 207 days, from filing on 9 May 2025 to dismissal on 2 December 2025. The use of Rule 41(a)(1)(A)(i) — which requires dismissal before the defendant answers — suggests the case resolved before substantive motion practice, indicating a relatively short and cost-limited proceeding for both parties.
Novartis was represented by Alexandra M. Joyce and Daniel M. Silver of McCarter & English LLP. Lupin was represented by Alexandra M. Ewing and Frederick L. Cottrell III of Richards Layton & Finger PA. Judge John F. Murphy of the District of Delaware was assigned to the case.
PatSnap Eureka searches patents and litigation data to answer instantly.